乌司他丁对慢阻肺患者气道阻力及机体免疫的影响观察

Observation on the Influence of Ulinastatin for Airway Resistance and Body Immunity of Patients with Chronic Obstructive Pulmonary Disease

目的:研究乌司他丁对慢阻肺患者气道阻力及机体免疫的影响。方法:选取2018年1月-2020年7月102例慢阻肺患者,根据随机数字表法将其随机分为对照组和观察组,每组51例。对照组采用常规治疗,观察组在对照组的基础上加用乌司他丁。比较两组治疗前及治疗3、7 d的CAT评分结果、气道阻力指标[气道阻力(Raw)、比气道阻力sRAW及气道传导率(Gaw)]、机体免疫指标(CD3^(+)、CD4^(+)、CD8^(+))及红细胞免疫指标[免疫黏附促进因子(FEER)、免疫黏附抑制因子(FEIR)、红细胞C3b受体(RBC-C3bR)]。结果:治疗前,两组的CAT评分结果比较,差异无统计学意义(P>0.05);治疗3、7 d,观察组的CAT评分结果均优于对照组,差异均有统计学意义(P<0.05)。治疗前,两组Raw、sRAW、Gaw、CD3^(+)、CD4^(+)、CD8^(+)、FEER、FEIR、RBC-C3bR比较,差异均无统计学意义(P>0.05);治疗3、7 d,两组Gaw、CD3^(+)、CD4^(+)、FEER、RBC-C3bR均高于治疗前,Raw、sRAW、CD8^(+)、FEIR均低于治疗前,且观察组Gaw、CD3^(+)、CD4^(+)、FEIR、RBC-C3bR均高于对照组,sRAW、Gaw、CD8^(+)、FEIR均低于对照组,差异均有统计学意义(P<0.05)。结论:乌司他丁可改善慢阻肺患者的气道阻力及机体免疫,对于疾病控制效果较好,因此在慢阻肺患者中具有较高的应用价值。

Objective:To study the influence of Ulinastatin for airway resistance and body immunity of patients with chronic obstructive pulmonary disease.Method:A total of 102 patients with chronic obstructive pulmonary disease from January 2018 to July 2020 were selected,and they were randomly divided into control group and observation group according to method of random number table,51 cases in each group.The control group was treated with routine treatment,and the observation group was treated with Ulinastatin on the basis of control group.Then the CAT scores,airway resistance indexes (Raw,sRAW,Gaw),body immunity state (CD3^(+),CD4^(+),CD8^(+)) and erythrocyte immunity (FEER、FEIR、RBC-C3bR) before treatment and 3,7 d after treatment were compared between two groups.Result:Before treatment,there was no statistically significant difference in CAT scores between the two groups (P>0.05);3 and 7 d after treatment,the CAT scores of the observation group were superior than those of the control group,and the differences were statistically significant (P<0.05).Before treatment,there was no statistically significant difference in Raw,sRAW,Gaw,CD3^(+),CD4^(+),CD8^(+),FEER,FEIR,RBC-C3bR between the two groups (P>0.05);3 and 7 d after treatment,the Gaw,CD3^(+),CD4^(+),FEER and RBC-C3bR of both group were higher than those before treatment,Raw,sRAW,CD8^(+),FEIR were lower than those before treatment,and the Gaw,CD3^(+),CD4^(+),FEER and RBC-C3bR of the observation group were higher than those of the control group,the Raw,sRAW,CD8^(+),FEIR were lower than those of the control group,the differences were statistically significant (P<0.05).Conclusion:The Ulinastatin can significantly improve the airway resistance and body immunity of patients with chronic obstructive pulmonary disease,and its control effect for the disease is better,so its application value in the patients with chronic obstructive pulmonary disease is higher.